Clinical Trial Search

Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 53.9; 54.6 µM*hr

Primary: Tidal Volume (ml) — 954.8; 554.4; 893.5; 542.9 tidal volume (ml)

Primary: Number and Frequency of Dose Limiting Toxicities (DLTs) With High-dose Calcitriol in Combination With Temozolomide — 0; 0; 0 DLT

Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 99.2 Percentage of participants — p=<0.001

Primary: Pruritus Intensity Visual Analogue Scale Score at Week 32 — 8.8; 27.1 Units on a scale — p=0.0055

Primary: Number of Participants With Clinical Cure in Each Study Arm — 11; 8 Participants — p=0.420

Primary: Number of Participants With 7-day Point Prevalence Abstinence From Smoking at Week 4 — 12; 13; 9; 18 Participants

Primary: Depression Remission, as Measured by the Hamilton Rating Scale for Depression — 13; 5; 43; 12 number of remitted patients

Primary: Meningococcal Serum Bactericidal Antibodies/Assay (rSBA) Titers — 6868.8; 13014.9; 1945.8; 5494.6 Titers

Primary: Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose — 404.09; 408.92…

Primary: Condom Use/Unprotected Sex - Redefined as Sexual Risk - 12 Month Follow-up — 28; 18; 26; 40 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events — 2; 0 Participants

Primary: Tolerability Assessment of Test Products — 9; 10; 11; 1 Participants

Primary: Durability of Response (Maintenance of an ACR20 Response or Greater), Which Was Measured at Each Visit in Subjects of RA — 117 Participants